Viking Therapeutics Stock Plummets: What’s Behind the Drop?

Viking Therapeutics ( (VKTX) ) has fallen by -38.23%. Read on to learn why.

Viking Therapeutics has experienced a significant drop in its stock price over the past week, plummeting by 38.23%. This sharp decline follows the release of data from a Phase 2 clinical trial for their drug VK2735, which, despite meeting its primary and secondary endpoints, failed to impress investors. The trial showed promising weight loss results, but the market reacted negatively, possibly due to adverse events reported during the study.

The stock’s downturn is further compounded by negative corporate insider sentiment, with several insiders, including the CEO and CFO, selling shares recently. This insider activity may have contributed to investor unease, despite analysts maintaining a strong buy consensus on the stock. The average price target set by analysts suggests a significant upside potential, yet the current market sentiment remains bearish.

Despite the recent sell-off, some analysts believe the market’s reaction to the trial results was an overreaction. They argue that the long-term potential of VK2735 remains strong, and the stock could rebound as the company progresses with its clinical trials. Investors are advised to keep an eye on further developments and analyst ratings, which continue to reflect optimism about Viking Therapeutics’ future prospects.